TCRX

TSCAN THERAPEUTICS, INC.

TCRX · CIK 1783328 · Annual (10-K) · Last 4 years

Financial Trends

Revenue$3M
20212024
Net Income−$127M
20212024
Operating CF−$111M
20212024
Free Cash Flow−$115M
20212024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue$0.0B$0.0B$0.0B$0.0B
Cost of Revenue————
Gross Profit————
R&D Expense$0.1B$0.1B$0.1B$0.0B
SG&A Expense————
Operating Income$-0.1B$-0.1B$-0.1B$-0.0B
Net Income$-0.1B$-0.1B$-0.1B$-0.0B
EPS (Basic)$-1.14$-1.36$-2.75—
EPS (Diluted)$-1.14$-1.36$-2.75—

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$0.4B$0.3B$0.2B$0.2B
Current Assets$0.3B$0.2B$0.1B$0.2B
Cash & Equivalents$0.2B$0.1B$0.1B$0.2B
Total Liabilities$0.1B$0.1B$0.1B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.2B$0.2B$0.1B$0.2B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$-0.1B$-0.1B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.2B$0.1B$0.0B$0.2B
← Companies